Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a
standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute …

Retrospective studies have suggested that older adolescents and young adults (AYAs) with
acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric …

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …

At the intersection between children and older adults, the care of adolescent and young
adult (AYA) patients with acute lymphoblastic leukemia (ALL) poses unique challenges and …

The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic
leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based …

Adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) treated with
asparaginase-containing pediatric regimens are commonly overweight or obese. We …

Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative
acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We …

Simple Summary Around 90% of children diagnosed with acute lymphoblastic leukemia are
long-term survivors due to the efforts made in the last decades to tailor the chemotherapy …

As novel immunological treatments are gaining a foothold in the treatment of acute
lymphoblastic leukemia (ALL), it is elemental to examine ALL immunobiology in more detail …